Pharma Mar Company Profile (NASDAQ:PHMMF)

About Pharma Mar (NASDAQ:PHMMF)

Pharma Mar logo

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PHMMF
  • CUSIP: N/A
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: $4.42
  • 200 Day Moving Avg: $4.09
  • 52 Week Range: $2.40 - $4.80
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $222.8 million
  • Price / Sales: N/A
  • Book Value: $0.28 per share
  • Price / Book: 14.46
Profitability:
  • EBIDTA: ($12,830,000.00)
Misc:
  • Average Volume: 6,837 shs.
 

Frequently Asked Questions for Pharma Mar (NASDAQ:PHMMF)

What is Pharma Mar's stock symbol?

Pharma Mar trades on the NASDAQ under the ticker symbol "PHMMF."

Who are some of Pharma Mar's key competitors?

How do I buy Pharma Mar stock?

Shares of Pharma Mar can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pharma Mar's stock price today?

One share of Pharma Mar stock can currently be purchased for approximately $4.05.


MarketBeat Community Rating for Pharma Mar (NASDAQ PHMMF)
Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  34 (Vote Outperform)
Underperform Votes:  49 (Vote Underperform)
Total Votes:  83
MarketBeat's community ratings are surveys of what our community members think about Pharma Mar and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Pharma Mar (NASDAQ:PHMMF) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Pharma Mar (NASDAQ:PHMMF)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Pharma Mar (NASDAQ:PHMMF)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Pharma Mar (NASDAQ:PHMMF)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Pharma Mar (NASDAQ:PHMMF)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Pharma Mar (NASDAQ:PHMMF)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Pharma Mar (NASDAQ:PHMMF)
Latest Headlines for Pharma Mar (NASDAQ:PHMMF)
Source:
DateHeadline
finance.yahoo.com logoPharmaMar Starts Clinical Studies with a New Compound -PM14- in Patients with Solid Tumors
finance.yahoo.com - September 20 at 7:44 AM
finance.yahoo.com logoPharmaMar Starts Clinical Studies with a New Compound -PM14- in Patients with Solid Tumors
finance.yahoo.com - September 20 at 7:44 AM
americanbankingnews.com logoPharma Mar (PHMMF) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - September 16 at 8:40 AM
finance.yahoo.com logoNew Positive Data on PM1183 Sees a Response Rate of 36% as Single Agent in Patients With Advanced and Relapsed Small-Cell Lung Cancer
finance.yahoo.com - September 12 at 8:35 AM
americanbankingnews.com logoPharma Mar (PHMMF) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - September 12 at 7:02 AM
americanbankingnews.com logoZacks Investment Research Downgrades Pharma Mar (PHMMF) to Hold
www.americanbankingnews.com - September 9 at 6:50 AM
finance.yahoo.com logoPharmaMar Will Present New Clinical Data on PM1183 During ESMO 2017
finance.yahoo.com - September 1 at 7:13 AM
americanbankingnews.com logoZacks Investment Research Lowers Pharma Mar (PHMMF) to Hold
www.americanbankingnews.com - August 20 at 9:56 AM
americanbankingnews.com logoPharma Mar (PHMMF) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - August 19 at 9:12 AM
americanbankingnews.com logo Pharma Mar (NASDAQ:PHMMF) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - August 15 at 12:28 AM
finance.yahoo.com logoPharmaMar Starts a Quadruple Combination Study With Aplidin® for the Treatment of Multiple Myeloma
finance.yahoo.com - August 10 at 6:49 AM
americanbankingnews.com logoZacks: Pharma Mar (NASDAQ:PHMMF) Given Consensus Rating of "" by Brokerages
www.americanbankingnews.com - July 29 at 12:35 PM
americanbankingnews.com logoZacks: Pharma Mar (PHMMF) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - July 14 at 11:18 AM
finance.yahoo.com logoFDA Chooses Zepsyre™ (PM1183) from PharmaMar to Explore Potential Development for Pediatric Cancers
finance.yahoo.com - June 21 at 1:38 AM
americanbankingnews.com logo Pharma Mar (PHMMF) Receives Consensus Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - June 19 at 4:14 PM
finance.yahoo.com logoPharmaMar Will Commercialize PM1183 With the Trade Name of Zepsyre™
finance.yahoo.com - June 16 at 8:56 AM
americanbankingnews.com logoPharma Mar (PHMMF) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - June 6 at 7:06 AM
finance.yahoo.com logoSylentis Initiates a Phase III Study for the Treatment of Dry Eye Syndrome
finance.yahoo.com - June 1 at 8:02 PM
americanbankingnews.com logoPharma Mar (PHMMF) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - May 27 at 8:52 PM
americanbankingnews.com logo Pharma Mar (PHMMF) Receives Average Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - May 26 at 8:51 AM
finance.yahoo.com logoPharmaMar and Eczacıbaşı Sign a Licensing Agreement for Aplidin® in Turkey
finance.yahoo.com - May 26 at 6:00 AM
finance.yahoo.com logoPharmaMar Announces New Data with its Compounds Yondelis® and Lurbinectedin During ASCO 2017
finance.yahoo.com - May 19 at 11:59 AM
americanbankingnews.com logo Pharma Mar (PHMMF) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - May 9 at 10:52 AM
finance.yahoo.com logoPharmaMar: Aplidin® Receives Orphan Drug Status for the Treatment of Multiple Myeloma in Switzerland
finance.yahoo.com - May 4 at 7:25 PM
americanbankingnews.com logoZacks: Pharma Mar (PHMMF) Receives Average Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - April 21 at 9:20 AM
americanbankingnews.com logoPharma Mar (PHMMF) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - April 12 at 7:36 AM
finance.yahoo.com logoPharmaMar Presents New Data on the Treatment of Multiple myeloma and Ovarian Cancer at the AACR Congress
finance.yahoo.com - April 7 at 11:53 AM
finance.yahoo.com logoPharmaMar to Host Research and Development Event on April 24, 2017
finance.yahoo.com - April 7 at 11:53 AM
americanbankingnews.com logoZacks: Pharma Mar (PHMMF) Given Average Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - April 6 at 5:09 PM
americanbankingnews.com logoPharma Mar (PHMMF) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - April 4 at 8:59 AM
americanbankingnews.com logoPharma Mar (PHMMF) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - March 30 at 12:04 AM
americanbankingnews.com logoPharma Mar (PHMMF) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - March 27 at 10:08 AM
americanbankingnews.com logoPharma Mar (PHMMF) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - March 25 at 2:39 PM
americanbankingnews.com logo Pharma Mar (PHMMF) Receives Average Recommendation of "" from Analysts
www.americanbankingnews.com - March 22 at 11:22 AM
seekingalpha.com logoTalking With PharmaMar's Management About Its Upcoming Pivotal Year
seekingalpha.com - March 16 at 7:56 PM
finance.yahoo.com logoPharmaMar Announces the Start of a Pivotal Study With plitidepsin in angioimmunoblastic T-cell lymphoma
finance.yahoo.com - January 25 at 1:01 AM
finance.yahoo.com logoPharmaMar Initiates a Pivotal Phase III ATLANTIS Study with PM1183 in Combination with Doxorubicin in Patients with Small Cell Lung Cancer
finance.yahoo.com - January 25 at 1:01 AM
finance.yahoo.com logoPharmaMar Announces the IDMC´s Response on the CORAIL Trial Using PM1183
finance.yahoo.com - January 25 at 1:01 AM
finance.yahoo.com logoPharmaMar Submits MAA to EMA for Aplidin® for the Treatment of Multiple Myeloma
finance.yahoo.com - January 25 at 1:01 AM
finance.yahoo.com logoPharmaMar and Boryung Pharm Sign a Licensing Agreement for Aplidin® (plitidepsin) in Korea
finance.yahoo.com - January 25 at 1:01 AM
finance.yahoo.com logoPharmaMar Shows New Clinical Data on Yondelis® and Lurbinectedin at ESMO 2016
finance.yahoo.com - January 25 at 1:01 AM
finance.yahoo.com logoPharmaMar Announces Positive Results From its Phase II Study With lurbinectedin in BRCA 1/2 - Associated Metastatic Breast Cancer at the ESMO 2016 Congress
finance.yahoo.com - January 25 at 1:01 AM
finance.yahoo.com logoPharmaMar Completes the Patient Recruitment for the "CORAIL" Phase III Pivotal Study With PM1183
finance.yahoo.com - January 25 at 1:01 AM
finance.yahoo.com logoPharmaMar Announces the Opening of a New Affiliate in Austria
finance.yahoo.com - January 25 at 1:01 AM
finance.yahoo.com logoThe EMA Accepts to Assess the Marketing Authorization Application from PharmaMar for Aplidin®
finance.yahoo.com - January 25 at 1:01 AM
finance.yahoo.com logoPharmaMar is Present at the 16th International Gynecologic Cancer Society Meeting With New Evidence on Yondelis®
finance.yahoo.com - January 25 at 1:01 AM
finance.yahoo.com logoPharmaMar Appoints Pascal Besman as Chief Operating Officer of PharmaMar U.S.
finance.yahoo.com - January 25 at 1:01 AM
finance.yahoo.com logoPharmaMar Begins a Phase I Study of PM1183 in Japan for the Treatment of Solid Tumors
finance.yahoo.com - January 25 at 1:01 AM
finance.yahoo.com logoPharmaMar Presents Positive Results With Its Conjugated Antibody MI130110 in CD13-Expressing Tumor-Cells
finance.yahoo.com - January 25 at 1:01 AM
finance.yahoo.com logoPharmaMar and Chugai Pharmaceutical Enter into a License and Commercialization Agreement for PM1183 in Japan
finance.yahoo.com - January 25 at 1:01 AM

Social

Chart

Pharma Mar (PHMMF) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by MarketBeat.com Staff